10-Q quarterly report · filed Nov 10, 2026

Liquidia Corp (LQDA) Q3 2026 10-Q Quarterly Report

Short answer

Liquidia Corp (LQDA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $225M (up 314.6% year over year) with net income of −$236M.

Q3 2026 key financials · XBRL

Revenue
$225M
+314.6% YoY · +31.2% QoQ
Net income
−$236M
−6589.2% YoY · −416.3% QoQ
Operating margin
-117.0%
EPS (diluted)
−$2.48
−8166.7% YoY · −435.1% QoQ

Source: XBRL data from the Liquidia Corp (LQDA) Q3 2026 10-Q on SEC EDGAR. USD.

Liquidia Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $225.3M, up $171.0M from $54.3M YoY, driven by YUTREPIA product sales
  • Product sales $222.7M vs $51.7M YoY, strongest line; service revenue $2.6M vs $2.7M
  • Operating loss $263.5M vs $1.8M income, including $389.7M litigation settlement charge
  • Cash provided by operations $279.9M vs $79.9M used YoY; investing use $32.0M, financing use $42.5M
  • PH-ILD label removal and promotion cessation, $105.4M cash restricted for UTC payments, further $145.4M payable by April 2027

Risk Factors

  • New trade-policy risk: April 2026 executive order sought 100% tariffs on imported branded or patented pharmaceuticals without U.S. manufacturing
  • Regulatory risk: Settlement Agreement removed PH-ILD from YUTREPIA’s label, narrowing its commercial opportunity versus Tyvaso
  • Competitive risk: Generic Tyvaso entered the market effective January 1, 2026
  • Financial risk: HCR facility requires minimum cash and cash equivalents of $45.0 million
  • Compliance risk: August 2026 SEC-FDA information-sharing agreement increased insider-trading enforcement exposure for FDA-related information

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Liquidia Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.